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Summary
Immunity is shaped by commensal microbiota. From early life onwards,
microbes colonize mucosal surfaces of the body and thereby trigger the
establishment of immune homeostasis and defense mechanisms. Recent
evidence reveals that the family of innate lymphoid cells (ILCs), which are
mainly located in mucosal tissues, are essential in the maintenance of bar-
rier functions as well as in the initiation of an appropriate immune
response upon pathogenic infection. In this review, we summarize recent
insights on the functional interaction of microbiota and ILCs at steady-
state and throughout life. Furthermore, we will discuss the interplay of
ILCs and the microbiota in mucosal infections focusing on intestinal
immunity.
Keywords: early life; infectious diseases; innate lymphoid cells; microbiota.
Abbreviations: AhR, arylhydrocarbon receptor; AOM, azoxymethane; CCR6, CC chemokine receptor 6; CD, cluster of differentia-
tion; CHILP, common helper ILC precursor; CLP, common lymphoid progenitor; DC, dendritic cell; ES, excretory secreted;
FRC, fibroblastic reticular cells; GF, germ-free; GM-CSF, granulocyte monocyte colony-stimulating factor; HAART, highly active
antiretroviral therapy; HpARI, Heligmosomoides polygyrus alarmin release inhibitor; IBD, inflammatory bowel disease; Id2, in-
hibitor of DNA-binding 2; IFN, interferon; IgA/G, immunoglobulin A/G; IL, interleukin; ILC, innate lymphoid cell; ILF, intesti-
nal lymphoid follicle; Lgr5, leucine-rich repeat-containing G-protein-coupled receptor 5; LTi cell, lymphoid tissue inducer cell;
MHC, major histocompatibility complex; NCR, NK cell receptor; NK cell, natural killer cell; pDC, plasmacytoid dendritic cell;
RA, retinoic acid; Rag, recombination-activated gene; Reg3, regenerating islet-derived protein 3; RORyt, retinoic acid-related
orphan receptor gT; SFB, segmented filamentous bacteria; SLO, secondary lymphoid organs; SPF, specific pathogen-free; Tfh, T
follicular helper cell; Th, T helper; TLR, Toll-like receptor; TNF, tumour necrosis factor; Treg, regulatory T-cell; TRUC,
Tbx21/Rag2/ ulcerative colitis; TSLP, thymic stromal lymphopoietin; WT, wild-type
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Introduction
The role of the immune system is to protect our body
from a variety of foreign and potentially harmful sub-
stances, which we are exposed to throughout life. This is
especially true at the inner and outer body surfaces, such
as the airways, the skin, the intestine and the urogenital
tract, where the body constantly encounters non-self-anti-
gens present in the food or the environment, potential
pathogens, and microbes naturally colonizing these sur-
faces. The latter consist of bacteria, viruses, archaea and
fungi, collectively referred to as commensal microbiota.
Colonization with commensal microbiota starts at
birth, when the newborn leaves the sterile environment of
the womb and gets in contact with the first colonizing
bacteria in the birth canal. Throughout the first 1–2 years
of life, the human microbiota is rather unstable and sub-
ject to change, before it reaches an astonishingly stable
composition that stays throughout adulthood if external
factors, such as diet, hygiene and health state are unal-
tered. It is only in the elderly, that the composition of
the human microbiota commences to change again.1,2
Commensal microbiota and the host live in a mutualistic
relationship. While the microbiota contributes to diges-
tive functions of the host, produces important vitamins,
for example vitamin K and B group vitamins, and pro-
tects the body from invasion with pathogens, it also
importantly matures the host immune system, both at
mucosal and systemic sites (for reviews, see Refs3,4). The
presence of such high numbers of bacteria in and on the
mammalian body is also potentially harmful, as they
might induce inflammatory responses. Tight barriers and
regulatory mechanisms need to be in place in order to
prevent invasion of the microbes into the body and inap-
propriate inflammatory reactions, respectively.
Components of the innate immune system are predom-
inantly present at mucosal sites and help maintain the
hostcommensal mutualism. Besides mechanical barriers,
such as tight junctions between the intestinal epithelial
cells and mucus produced by goblet cells, haematopoietic
cells, such as mononuclear cells and innate lymphoid cells
(ILCs), are important effector cells of the innate immune
system.3 ILCs derive from the common lymphoid progen-
itor in the bone marrow and are by definition lympho-
cytes. They are predominantly found at mucosal sites,
such as the intestine and the airways, react fast during an
immune response, and lack antigen-specific receptors –
all typical features of innate immune cells.5 ILCs can be
classified into five subsets, type 1 ILCs (ILC1s), type 2
ILCs (ILC2s), type 3 ILCs (ILC3s), lymphoid tissue indu-
cer cells (LTi), which are often classified as a subset of
ILC3s, and natural killer (NK) cells.6 ILC1s express the
transcription factor T-bet and produce interferon (IFN)-c
and tumour necrosis factor (TNF)-a. Similarly, NK cells
also express T-bet and produce IFN-c and TNF-a. In
addition, NK cells can lyse target cells in a cell-contact-
dependent manner through the release of perforin and
granzymes. Classical NK cells express the transcription
factor Eomes and are developmentally distinct from
ILC1s. Only a minor subset of Eomes-positive, granzyme
and perforin-expressing ILC1-like cells has been described
to be involved in tumour surveillance in mice.7 In addi-
tion, human intraepithelial ILC1s express Eomes.8,9
ILC2s are dependent on the expression of GATA-3 and
release mainly IL-5 and IL-13, thus contributing to T
helper (Th)2-responses. Both ILC3s and LTi cells are
characterized by the expression of the transcription fac-
tor retinoic acid-related orphan receptor gT (RORct).
While ILC3s produce IL-22, IL17A and IL17F, LTi cells
are mainly involved in lymphoid organ formation
through the production of lymphotoxins.6,10,11 Recently,
a regulatory ILC population, which also develops from
the common lymphoid progenitor (CLP) in an Id3-de-
pendent way, was described to be the main source of
immunomodulatory IL-10 in the intestine following
inflammation.12
Numerous functions of ILCs during homeostasis,
immune responses and diseases have been described, and
more are to be revealed. Interestingly, many of these
either involve signals from the commensal microbiota or
contribute to hostmicrobial mutualism. In the follow-
ing, we aimed to summarize identified interactions
between ILCs and the microbiota during health and dis-
ease throughout life.
ILC development and microbiota in prenatal and
early life
Although adult ILCs derive from the CLP in the bone
marrow giving rise to the inhibitor of DNA-binding 2
(Id2)+ common helper ILC precursor (CHILP), which
finally differentiates into all ILC subsets expect NK cells,13
certain fetal and perinatal ILCs can derive from a progen-
itor found in the fetal liver. RORyt-expressing LTi cells
were first identified at embryonic day E135–E155 in the
lymph node and Peyer’s patch anlagen to be responsible
for the induction of these secondary lymphoid organs
(SLO).14–18 The formation of these early LTi cells seems
to be independent of the presence of the commensal
microbiota as germ-free (GF) mice harbour normal num-
bers of lymph nodes and Peyer’s patches.16,19 In contrast,
maternal dietary components, such as retinoic acid (RA),
were shown to be crucial to maintain this LTi cell popu-
lation during fetal development and consequently for the
correct induction of SLO.20 Interestingly, microbiota is
directly regulating the availability of RA.21 Specifically,
Clostridia species influence epithelial RA synthesis.22 A
similar population of RORyt+ ILC3s is required to induce
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cryptopatches and intestinal lymphoid follicles (ILFs)
after birth.23–26 Lin IL-7Ra+ Flt3 a4b7
+ progenitors pre-
sent in the fetal liver can give rise to ILC3s that can be
found in the intestinal lamina propria at the time of
birth.27,28 The population of RORyt-expressing ILCs in
the lamina propria shortly after birth consists of mainly
CCR6+ c-kithi LTi cells, which seed the intestinal lamina
propria during fetal development, and low numbers of
CCR6c-kitlo ILC3s that expand strongly within the first
2–4 weeks of birth and that can acquire NK cell mark-
ers.29,30 The expansion of the latter was shown to be
dependent on signals originating from the maternal
microbiota as shown in a model of reversible gestational
colonization during pregnancy.31 Arylhydrocarbon recep-
tor (AhR) ligands produced by the maternal microbiota
were transferred to the offspring postnatally through the
milk and permanently increased the absolute number of
NKp46+ ILC3s in the offspring small intestinal lamina
propria starting at postnatal day 14. This is in line with
three studies comparing adult specific pathogen-free
(SPF) and GF mice, which reported a reduced number
of intestinal lamina propria NCR+ ILC3s in GF mice.32–34
This area is, however, subject to controversy as other
studies showed a negative influence of missing microbiota
on the different ILC3 subsets.35 In a separate study using
RORcCre 9 AhRfl/fl mice and experimentally purified
AhR-ligand-enriched or depleted diets, it was demon-
strated that CCR6 ILC3s were strongly reduced in num-
bers in the absence of any Ahr signalling, which resulted
in the absence of intestinal cryptopatches and ILFs.36 Nat-
ural ligands of the AhR include agonists derived from
cruciferous vegetables in the diet as well as indoles pro-
duced by members of the microbiota. Although, this
study did not investigate the influence of microbiota-
derived Ahr ligands on the proliferation of CCR6 ILC3s,
it is likely to speculate that AhR ligands derived from not
only the maternal microbiota but also from the endoge-
nous microbiota of the offspring contribute to the home-
ostasis of this ILC population. This is supported by the
observation that GF mice show a delay in the maturation
of cryptopatches into ILFs.37 A high degree of plasticity
has been described for intestinal ILC3s. While the T-bet
induced upregulation of NK cell receptors (NCRs) on
ILC3s was dependent on the presence of the commensal
microbiota as described above,13,32,34 the loss of RORyt-
expression in NCR+ ILC3s and their switch to a more
ILC1-like phenotype was prevented in colonized com-
pared with GF mice.33
A recent publication showed that perinatal signals lead-
ing to expansion of neonatal ILC2s are important to
maintain even the adult pool of ILC2s.38 This perinatal
expansion of ILC2s was independent of commensal
microbiota as it occurred also in GF mice. As interactions
between an individual SPF consortium and a defined diet
are very complex, it is not unlikely that a combination of
dietary and microbial signals contributes to this event. It
is also known that ILC2 numbers in the intestine of GF
adult mice are higher compared with those in colonized
animals, reflecting the general shift towards Th2-type
immune responses in GF mice.39 In contrast to the ILC3s,
transient maternal microbial exposure during gestation
did not change the ILC2 numbers in the offspring
intestine.31
The role of microbiota in the differentiation of ILC1s
and NK cells during early life has not been investigated
in detail. However, cell numbers in the different lym-
phoid organs were unaffected by the commensal micro-
biota both in young and adult mice wherever
investigated.40 A study on the human ILC1 subset by
Spits and colleagues has suggested that colonization of
the neonatal intestine is triggered through microbiota
colonization after birth as this subset seems absent in
the fetal intestine. In addition, they show that this ILC1
subset has the potential to differentiate into RORct-ex-
pressing ILC3 during adulthood in the presence of IL-23
and RA, the latter being partially regulated by the com-
mensal microbiota.41
A study by Gury-BenAri et al. has characterized 15 dif-
ferent existing intestinal ILC subsets at single cell level in
regard to transcriptomic activity and chromatin landscape
in SPF, GF and antibiotic-treated mice. While antibiotic-
treated and GF mice exhibited ILC subsets with very sim-
ilar expression profiles, colonized animals clustered sepa-
rately in most subsets. ILC1 and ILC2 subsets were most
affected by the absence of commensal microbiota and
acquired a phenotype that more closely resembled ILC3
subsets.42 In conclusion, while ILC3s seem to be mainly
influenced by microbial signals during early life, ILC2s
and ILC1s are more shaped through microbiota during
adulthood (Fig. 1).
Microbiota and ILC interactions during steady-
state in adulthood
Contribution of microbiota to the establishment of a
physical barrier: epithelial integrity
The different ILC subsets are predominantly found at
mucosal sites, and the intestinal lamina propria is home
to all three main subsets of ILCs: ILC1s, ILC2s and
ILC3s. One of the first discovered functions of ILCs is
their role in maintaining a tight and healthy intestinal
barrier, and thus contributing to control the intestinal
microbiota. ILC3 produce the cytokine IL-22, which can
act on the IL-22 receptor expressed exclusively on non-
haematopoietic cells in the gut, mainly intestinal epithe-
lial cells.43 IL-22 predominantly acts on Paneth cells to
induce the release of the antimicrobial proteins Reg3b,
Reg3y, S100A8, S100A9.44 IL-22 produced by ILCs was
also shown to enhance proliferation of Lgr5+ intestinal
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epithelial stem cells in murine and human organoids
and in an in vivo mouse model.45 Recently, Gronke
et al. demonstrated that ILC3-derived IL-22 induces the
DNA damage response in intestinal epithelial cells, pro-
tecting the epithelial layer from exogenous genotoxic
stress, thus limiting tumorigenesis.46 The production of
IL-22 by both CCR6 and CCR6+ ILC3s is stimulated
by commensal microbiota as shown by the use of GF
and antibiotic-treated mice.29 ILC3-derived IL-22
induces the expression of various other factors in the
epithelium, including tight and gap junction proteins,
mucins, and cytokine receptors that contribute to the
homeostasis and barrier function of the epithelium (for
review, see Ref.47). Two reports illustrated that ILC3s
are crucial in preventing dissemination of intestinal
commensals to peripheral tissues: the titres of serum
IgG specific for intestinal commensal bacteria were ele-
vated in RORyt-deficient mice,48 and Rag/ mice
exhibited systemic translocation of Alcaligenes species
and systemic inflammation upon depletion of ILCs using
anti-Thy1 antibodies.49
Epithelial-derived cytokines, such as IL-25, IL-33 and
thymic stromal lymphopoietin (TSLP), are regulated by
commensal microbiota and act on ILC2 maintenance and
function.35,50 IL-13 produced by ILC2s can act on intesti-
nal epithelial stem cells and bias their differentiation into
goblet cells and tuft cells, promoting mucus production
by goblet cells and environmental sensing capacities of
the intestinal epithelium through tuft cells. A positive
feedback loop exists between ILC2s and Tuft cells as
ILC2-derived IL-13 induces further IL-25 secretion by
Tuft cells.51 In addition, IL-13 secreted by ILC2s supports
self-renewal of intestinal epithelial stem cells.52
IFN-c and TNF-a, which are also produced by T-bet+
ILC1s, are known to increase permeability of the intesti-
nal epithelial cell barrier as shown in bacterial transloca-
tion studies using monolayers of human intestinal
epithelial cells.53,54 The absence of T-bet in the innate
immune system also directly affects microbiota composi-
tion as presented further down.
As outlined above, one main function of ILCs lies within
the strengthening of epithelial barriers at mucosal surfaces
ILC1
ILC3
ILC2
Fetal development AdulthoodNeonatal / Early life
Maternal microbiota/diet Microbiota-derived metabolites
in maternal milk +
endogenous microbiota
Endogenous
microbiota
Figure 1. Influence of the commensal microbiota on innate lymphoid cells (ILCs) throughout life. Although mammals get colonized with com-
mensal microbiota at the time of birth, microbial signals originating from the maternal microbiota can reach the offspring already during the
fetal stage via the placenta and during neonatal life through maternal milk. In addition, both ILC3s and ILC2s have been described in the fetal
liver. Microbial influences on ILC development, maintenance and function are thus possible throughout life. The current knowledge on microbial
influences on ILC numbers and functions was used to estimate the importance of commensal microbiota-derived signals on intestinal ILCs at the
different stages of life (fetal, neonatal, adult). The strength/importance of the microbial influence is indicated here by the shade of green colour
used in the arrows. ILC3s seem to be the ILC population that is most strongly dependent on microbial signals, and these are especially important
in establishing the intestinal ILC3 pool during early life through signals originating also from the maternal microbiota during pregnancy. ILC2s
are generally slightly less dependent on the presence of commensal microbiota, especially in early life. However, a slight increase in cell numbers
has been described in adult germ-free (GF) mice. ILC1s are believed to be absent during fetal life, and the influence of microbiota appears to be
stronger the more mature and possibly pro-inflammatory the intestinal microbiota has become.
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through various mechanisms and thus regulating the
translocation of microbial members into the body. This is
supported by the location of most ILCs within mucosal tis-
sues and the resulting proximity to such epithelial barriers.
Microbiota, ILCs and other members of the innate
immune system
Innate lymphoid cells (ILCs) carry several cytokine
receptors and can thus react to cytokines released by
other innate immune cells. Intestinal mononuclear
phagocytes produce IL-23, IL-1a and IL-1b in a micro-
biota-dependent manner, which induce IL-22 and IL-17
production by ILC3s.55–58 These cytokines are mainly
released by CX3CR1+ macrophages and CD103+
CD11b+ dendritic cells (DCs) resident in the intestinal
lamina propria.57,59,60 Microbiota-induced IL-1b also
induces the release of granulocyte monocyte colony-
stimulating factor (GM-CSF) by ILC3, which in turn
promotes mononuclear phagocytes to produce regula-
tory components, such as IL-10 and RA.57 The latter
are important to promote regulatory T-cell (Treg) dif-
ferentiation and expansion in the intestine to ensure
intestinal homeostasis.
Splenic NK cells in GF and antibiotic-treated mice are
largely unresponsive when stimulated to produce IFN-c
or exert specific lysis of target cells following Toll-like
receptor (TLR) ligand exposure in vivo. This was due to
functionally impaired DCs in the absence of microbiota
that were unable to produce the NK priming cytokines
IFN-I and IL-15.40
Microbiota, ILCs and adaptive immune responses
While ILC function is influenced by commensal micro-
biota, ILCs themselves can influence adaptive immune
cells, which in return help keeping the hostmicrobial
mutualism in check. The largest set of data is available on
the role of ILC3s in regulating T- and B-cell responses.
The CCR6+ subset of ILC3s present in the colonic lamina
propria and mesenteric lymph nodes expresses major his-
tocompatibility complex (MHC)-II and can act as anti-
gen-presenting cells to negatively select commensal
bacteria-specific CD4+ T-cells. The elimination of micro-
biota-specific T-cells was very important to prevent low-
grade systemic and spontaneous intestinal inflamma-
tion.61,62 An independent study demonstrated that splenic
but not intestinal MHC-II-expressing ILC3s can be acti-
vated through microbiota-derived IL-1b to express co-
stimulator molecules and thus drive CD4+ T-cell and B-
cell responses in vivo.63 Similarly, microbiota-derived sig-
nals during colitis induced the expression of the co-stim-
ulatory molecule OX40 on MHC-II-expressing ILC3s,
which could subsequently activate intestinal T-cells.64
ILC3s were also shown to localize within the MLN to the
interface between the T- and B-cell zone to regulate T fol-
licular helper cell (Tfh)-dependent germinal centre reac-
tions.65 This was dependent on MHC-II expression and
antigen presentation by ILC3s and significantly reduced
colonic IgA+ B-cell responses to commensal microbiota,
thereby contributing to hostcommensal mutualism.66 At
the same time, lymphotoxin alpha expression by ILC3s
was critical to control T-cell homing to the gut, repre-
senting another influence of ILC3s on T-dependent IgA
production.67 However, ILC3s not only affect T-depen-
dent, but also T-independent IgA induction via the pro-
duction of BAFF and APRIL in the spleen,68 and
through expression of the lymphotoxin beta receptor and
interaction with DCs in intestinal lymphoid follicles.69
ILC2s can likewise influence CD4+ T-cell responses.
ILC2s were shown to skew CD4+ T-cell differentiation
and activation towards Th2 instead of Th1 in a cellcell
contact dependent manner.70–72 A subset of ILC2s also
express MHC-II and can present antigens to CD4+ T-
cells.70,71 ILC2s could potentially also affect the genera-
tion of intestinal IgA, and therefore influence commensal
microbiota, through the release of IL-5, which is favour-
able for IgA induction in B cells, and through IL-6 that
promotes B-1 cell proliferation.73
Impact of ILCs on microbiota composition
Knowing that ILCs have direct effects on intestinal barrier
integrity on several levels, including the regulation of
intestinal epithelial cells, of innate immune populations
and of adaptive immune responses, it is expected that the
absence of one or several ILC populations goes along with
an altered hostmicrobial mutualism and ultimately with
microbial dysbiosis. Still, only few studies are available
that have addressed commensal microbiota composition
in mice deficient in ILC populations or with altered ILC
function. Such studies are also challenging as cage effects
are prone to affect the results, and the requirement for
littermates can be a limiting factor and is often
neglected.74,75 While microbiota diversity and phylum
composition were unaltered in the absence of ILC3s
(RORcCre 9 Id2fl/fl), these mice exhibited higher levels of
segmented filamentous bacteria (SFB) as well as Clostridi-
ales species.76 Mice lacking the AhR in ILC3s, which goes
along with reduced numbers of ILC3s, or lymphotoxin
alpha in ILC3s, also carried more SFB,67,77 corroborating
the hypothesis that SFB, which are associated with a Th-
17-mediated inflammatory phenotype,78 are under control
of ILC3s. Several studies addressed microbiota composi-
tion in models of IL-22 deficiencies. IL-22-deficient mice
harboured a dysbiotic colonic microbiota with colitogenic
potential compared with wild-type (WT) control mice,
which was transmissible to WT animals if adult animals
of the two strains were co-housed.79 Unfortunately, no
littermates were addressed to understand the role of IL-22
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in protecting from the acquisition of a colitogenic micro-
biota in early life as it has been shown for the presence of
TLR5 in the neonatal period.80 Another study demon-
strated that Id2 expression in ILC3s was important for
the generation of IL-22, which maintained a healthy
microbiota that exhibited early colonization resistance to
Citrobacter rodentium.76 ILC3s in the skin were recently
shown to control the growth of the sebaceous glands and
consequently the release of antimicrobial lipids, enabling
the establishment of a healthy skin microbiota.81
T-bet depletion in Rag/ mice exhibited commensal
dysbiosis associated with susceptibility to colitis in one
but not another mouse colony.82,83 Since a subset of
ILC3s, ILC1s, and NK cells express or depend on the
transcription factor T-bet, it is difficult to know which
ILC subset is responsible for this phenotype. T-bet
depletion in the innate immune system in the colony
harbouring the colitic microbiota went along with stron-
ger IL-17 expression by the remaining ILC3s.83 In a later
study, if T-bet was depleted ubiquitously (Tbx21/) or
in NCR+ ILCs (Ncr1iCreTg 9 Tbx21fl/fl) in either
immunocompetent or compromised mice, ILC2 fre-
quency and function in the colonic lamina propria,
spleen and lymph nodes were increased, promoting pro-
tective mucosal immunity during worm infections.84
This was mediated through increased IL7Ra expression
by ILC2s in the absence of T-bet. To our knowledge,
intestinal microbiota composition in ILC2-deficient mice
has not yet been investigated.
Microbiota – ILC axis during infectious diseases
Microbiota and ILCs in parasitic infections
Helminth infections
Approximately one-third of the world’s population is
infected with helminths.85 Helminth infections greatly
influence the host’s immune response and dampen immu-
nity to co-infections.86 Type 2 signature cytokines are
induced triggering goblet cell differentiation, mucin release
and smooth muscle contraction commonly referred to as
‘weep and sweep’ mechanism to expel helminths. Not sur-
prisingly, helminth infections disturb the microbial compo-
sition of the host. Depending on the infecting helminth,
different shifts of the microbiota towards specific bacterial
species have been reported with an imbalance of Lacto-
bacilli species in C57BL/6 laboratory mice.87,88 Helminths
are also able to act directly on the host’s immune response
by the release of excretory secreted (ES) vesicles carrying
several different immunomodulators.89 Upon helminth
infections, intestinal ILC2s are activated mainly by alarmins
such as IL-25 and IL-33.90,91 Indeed, ILC2s have been firstly
identified in detail upon infection with the intestinal hel-
minth Nippostrongylus brasiliensis (N. brasiliensis).73,92,93
Due to their fast release of type 2 cytokines, such as IL-13,
ILC2s accelerate worm expulsion by triggering epithelial
immunity. Release of tuft cell-derived IL-25 activates ILC2s
to increase IL-13 expression, which then again acts on the
epithelium. This positive feedback loop of cooperate action
of ILC2s and epithelial cells is key to expel and eliminate
the pathogen.51,94,95 However, helminth-derived Heligmo-
somoides polygyrus alarmin release inhibitor (HpARI),
which is able to neutralize ILC2 activating IL-33, damp-
ens protective type 2 immunity.96 Whether ILC popula-
tions and specifically ILC2s are able to directly sense and
react to helminth-derived ES vesicles will be of great inter-
est for future studies. Helminth infections can trigger mal-
nutrition and worsen disorders including vitamin A
deficiency. The vitamin A metabolite RA is essential for the
intestinal immune response upon infection: decreased ILC3
levels but increased number and activity of ILC2s, such as
increased IL-13 secretion, have been reported in helminth
infections (Trichuris muris; T. muris) in vitamin A-insuffi-
cient mice.97 The metabolism of ILC2 relies highly on fatty
acid metabolism at steady-state as well as upon T. muris
infection on RA-triggered malnutrition.98 AhR-deficient
ILC2s show enhanced activity and thereby acceleration of
clearance of helminths (Heligmosomoides polygyrus bak-
eri).99 This is due to decreased recruitment of the transcrip-
tional determinant Gfi1 to the Il1rl1 locus in genetically
induced AhR-deleted ILC2s.
Toxoplasma gondii
The intracellular parasite Toxoplasma gondii (T. gondii) is
mainly transmitted in the cyst stage, and induces dysbio-
sis and a shift of the microbiota to Enterobacteriaceae.100
A strong type 1 immune response is generated by IFN-c
producing innate and adaptive lymphoid cells. Indeed, T-
bet-dependent ILC1s are able to control T. gondii infec-
tions by their release of IFN-c and TNF-a.13 An addi-
tional T-bet-dependent population of intraepithelial
lymphocytes with an ILC1 profile has been reported
recently.101 These NKp46 CD8aa Ly49E+ IELs express
IFN-c upon T. gondii infection, and thereby promote the
type 1 immune response to eliminate T. gondii. A recent
report identified plasticity of NK cells to ILC1s using
Eomes-fate-map mice in T. gondii infection highlighting
how closely related these populations are.102 Moreover,
not only parasitic but also bacterial and viral infections
impact on microbiota composition and ILCs functionality
(Fig. 2), which will be discussed in the next paragraphs.
Microbiota and ILCs in bacterial infections
Gram-positive bacteria – Clostridium difficile infections
Microbiota is severely reduced and colonization resistance
lost upon broad-spectrum antibiotics treatment, which
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increases the susceptibility to infection by the Gram-posi-
tive bacterium Clostridium difficile (C. difficile). In North
America, C. difficile infects several hundred thousand
people every year, and represents an important health
threat especially for immune-compromised and hospital-
ized patients. Adaptive immune responses and innate
immunity cooperate to eliminate C. difficile, which estab-
lishes its infection by the toxin-controlled inhibition of
epithelial GTPases thereby destroying the epithelial bar-
rier.103 Innate lymphoid populations are important in the
defense against C. difficile reported by studies in ILC-defi-
cient mice.104,105 Transfer experiments of ILCs revealed
that especially ILC1s and ILC3s contribute through the
secretion of IFN-c and IL-22 in the acute phase of C. dif-
ficile infection.104 In a recent report, an additional mecha-
nism based on IL-33 and its induction of ILC2s in C.
difficile infection was described: upregulation of IL-33
during infection induces ILC2s thereby acting as a protec-
tive immune mechanism. Furthermore, in human fecal
transplant patients, the transfer of microbiota induced IL-
33 and thereby triggered a protective immune
response.106 These reports indicate that all helper ILC
populations are involved in resolving C. difficile infec-
tions; however, their importance may be dependent on
the phase of the infection. As mentioned earlier, C. diffi-
cile infections are successfully treated by the therapeutic
approach of fecal transplants to restore microbiota and
eliminate the ecological niche for C. difficile.107 Whereas
this therapeutic approach has had great success, a current
trial has led to the death of one patient by transferring
microbiota including multi-resistant bacteria,108 underlin-
ing the need for accurate and detailed screening of poten-
tial pathogens in transplants. Conversely to the immune
response in C. difficile infections, it is still unknown
whether and to which extent ILCs contribute to the
short- and long-term changes upon fecal transplant in
humans.109 Moreover, susceptibility to C. difficile
increases with age; however, direct links to microbiota
dysbiosis and/or ILC populations have not yet been
reported in these conditions.
Gram-negative bacteria – Salmonella, Citrobacter and
Helicobacter infections
Non-typhoidal Salmonella (Gram-negative) species such
as Salmonella typhimurium are transmitted by contami-
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Figure 2. Intestinal infections lead to perturba-
tions of the microbiota and alter innate lym-
phoid cell (ILC) activity. Parasitic, bacterial
and viral infections influence microbiota com-
position and function as well as the activity of
ILCs. Depending on microbial components
and immunomodulators induced by pathogens,
the ILC activation can be protective or detri-
mental, resulting in either pathogen elimina-
tion or immunopathology, respectively.
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nated food. Intestinal infections occur fast, accompanied
by stomach pain and diarrhoea, and are usually cleared
within several days in healthy individuals. Direct links to
ILCs during Salmonella infections in humans have not
been reported, but it has been suggested that ILC1s play a
role based on the observation that ILC1s are not present
in the fetal human gut in contrast to ILC2s and ILC3s,
and thus may be triggered by commensal bacteria
acquired upon birth, which include Gram-negative bacte-
ria.110,111 In mice, S. typhimurium is only able to establish
an intestinal infection upon loss of the host’s colonization
resistance experimentally induced by a one-time treat-
ment with the antibiotic streptomycin.112 Upon Sal-
monella infection, adaptive and innate immunity
including epithelial cells and ILCs work in concert to
eliminate the bacteria. IFN-y is key to fight the infection,
and its expression has been reported to be shared by con-
ventional NK cells as well as ILC3s during Salmonella
infection in mice with T-bet+ CCR6 RORct+ ILC3s
being the strongest IFN-y producers.29 In addition,
intestinal IL-22 expression triggered by intestinal epithe-
lial cell-derived RA affects antimicrobial peptide expres-
sion and bacterial load in S. typhimurium infection.22
Enterohaemorrhagic Escherichia coli (EHEC) infections,
which are often detrimental in humans, are modelled by
infection with the Gram-negative bacterium C. rodentium
in mice. ILCs are essential in the defense against C. ro-
dentium on several levels. ILC-derived IL-22 acts on non-
haematopoietic cells to initiate an innate immune defense
program against C. rodentium.113,114 CD4+ LTi cells have
been identified as an important source of IL-22 upon
C. rodentium infection in mice115 as well as ILC3s, specif-
ically, CCR6low/ ILC3s. Interestingly, the latter popula-
tion is dependent on ligand-induced stimulation of AhR,
as discussed previously. Whereas ILC3s are supported by
AhR stimulation and needed to fight off C. rodentium
infection, ILC2s are inhibited by AhR signalling in hel-
minth infections.99 Retinoic acid is essential for ILC3
activity during C. rodentium infection. Vitamin A-insuffi-
cient mice are more susceptible to C. rodentium due to a
reduction in IL-22-expressing ILC3s.97
Antigen presentation by ILC3s via MHC-II is impor-
tant to maintain the mucosal barrier at steady-state, but
also upon infection. In mice lacking MHC-II in ILC3s,
infection with C. rodentium resulted in an increased Tfh
response, elevated levels of IgA and C. rodentium-specific
IgA underlining that LTi-like ILC3s are key in triggering
the adaptive immune response via regulation of IgA and
pathogen infections.66
In humans, the Gram-negative bacteria Helicobacter
pylori colonizes the stomach and intestine, but can also
trigger colon cancer when becoming pathogenic. Li et al.
reported an increase in Lin+ GATA3+ as well as
Lin GATA3+ ILC2-like populations together with a
more pronounced type 2 signature limiting the protective
type 1 immune response in the development of can-
cers.116 In mice, Helicobacter typhlonius infection triggers
IL-17A expressing ILCs by synergizing DCs derived TNF-
a and IL-23 in the Tbx21/Rag2/ ulcerative colitis
(TRUC) model.83
Microbiota and ILCs in viral infections
ssRNA viruses: Norovirus, mouse hepatitis virus and
influenza virus
Norovirus (family of Caliciviridae, ssRNA) infections are
highly contagious, and typical symptoms include diar-
rhoea, nausea, vomiting and abdominal pain in humans.
In mice, Murine Norovirus (MNV) triggers changes of
epithelial innate immunity of the small intestine in mice
hypomorphic for ATG16L expression.117,118 Because
ATG16L is a risk gene for Crohn’s disease in humans,
this report highlights the close link of genetic predisposi-
tion and microbial exposure. Interestingly, infections of
MNV in GF mice have identified an important role of
virus ‘colonization’ on the host immune system. Here,
MNV mimics beneficial immune modulatory function of
the microbiota and influences intestinal immune
responses as well as ILC numbers and function.39
Whether and how MNV infection impact on microbiota
and thereby immunity of ILC populations in SPF colo-
nized mice still needs to be investigated. However, upon
antibiotic treatment, MNV infection or sensing of viral
ssRNA by TLR7 is able to trigger antimicrobial peptide
expression as well as IL-23 release, and thus tightening of
the epithelial barrier together with increased ILC3 func-
tion in the defense against vancomycin-resistant Entero-
coccus faecium (VRE).119 Interestingly, treatment of
psoriasis with the TLR7-activating drug imiquimod has
been linked to colonic dysbiosis and thus to increased
susceptibility to DSS colitis.120 However, this was
not ILC3 dependent in contrast to reports from the pre-
viously discussed study.119
The pathogenic Mouse Hepatitis Virus (MHV; family
of Coronaviridae, ssRNA) targets the intestine and liver,
and is able to cause severe systemic disease. It is feared in
animal facilities as a contamination but also used success-
fully to study viral pathogenicity. Here, upon oral MHV
infection, fibroblastic reticular cells (FRCs) secrete IL-15
in a MyD88-dependent manner and thereby control
ILC1s and intestinal inflammation. Dysbiosis is observed
in the absence of innate immune stimulation, showing
that tissue circuits between non-haematopoietic cells,
such as FRCs and haematopoietic cells including ILC1s,
are key in intestinal immune responses against viruses.121
Although respiratory viruses, including influenza virus
(ssRNA), are limited to the airways during infection
and have been reported to impact systemic immunity
and the intestinal microbiota.122,123 Indeed, immunity
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and microbiota of the gut and lungs are closely inter-
linked.124 In humans, the microbiome of the upper respi-
ratory tract, including nose and throat, has been shown
to change upon influenza infection.125 Whether intestinal
ILC populations are affected in influenza infection in
humans has not yet been addressed. However, ILCs,
specifically ILC2s, are increased upon infection with influ-
enza A virus (IAV) in the respiratory tract in mice.126–128
IAV-induced ILC2s can be detrimental for the host by
inducing excessive type 2 immune responses and airway
hyperreactivity independently of the adaptive immune
system. Control of ILC2s by IFN is thus an important
mechanism to restrain ILC2s upon IAV infection.127
However, ILC2s can also support wound healing upon
infection by the secretion of AREG in the respiratory tract
as well as in the gut during inflammation, and thereby be
beneficial for the host.126,129 Experimental factors might
be involved in the different outcome of the ILC2 charac-
ter including the use of different IAV subtypes in the
studies, namely H3N1 and H1N1, or general variations in
experimental procedures such as the different experimen-
tal time points analysed as previously discussed.130,131
Antibiotic treatment influences not only the microbial
composition in the gut (discussed above), but also has an
important impact on ILC plasticity and function,42 as
well as on immunity to respiratory infections, such as
influenza virus.132 Here, reduced signalling via the
inflammasome and TLRs leads to decreased activation
and migration of DCs into the mediastinal lymph node.
Thereby, the priming of T-cells is reduced and the initia-
tion of the immune response hampered. Moreover,
reduced levels of virus-specific T-cells to influenza virus
were reported by Abt and colleagues due to changes in
macrophage function in antibiotic-treated mice.133 Con-
versely, IAV infection has been reported to not be influ-
enced by antibiotic treatment in immature mice.134
However, how antibiotic treatment influences pulmonary
ILCs in pathogenic infections remains to be elucidated.
Lentiviruses: Human immunodeficiency virus and simian
immunodeficiency virus
Infection by human immunodeficiency virus (HIV; family
of Retroviridae, ssRNA) leads to acquired immunodefi-
ciency syndrome (AIDS), an immunodeficiency character-
ized by a severe reduction of CD4 T-cells. Highly active
antiretroviral therapy (HAART) is used successfully to
restrict viral load and maintain CD4 T-cells. Studies to
decipher the underlying mechanism in HIV infections
include studying simian immunodeficiency virus (SIV)-
infected non-human primates, HIV-infected humanized
mice and peripheral blood, as well as biopsies of HIV-in-
fected human individuals. HIV and SIV infection break
down the intestinal barrier leading to disruption of the
intestinal integrity and transition of intestinal antigens
followed by systemic inflammation.135 Patients with HIV
infections have been reported with perturbations of the
bacterial microbiota together with expansion of the vir-
ome.136 Upon HIV/SIV infection, intestinal CD4 T-cells
as well as ILC populations, specifically ILC3s, are mas-
sively decreased.137 HIV is not able to directly infect ILCs
as they lack both co-receptors used by HIV for viral
docking, namely CCR5 and CD4. However, human
CD45+ Lin CD117 CRTH2 CD127+ CD56 CD4+
cells can still be infected by HIV.138 In acute HIV infec-
tion, ILC1s, ILC2s and ILC3s are significantly decreased
in peripheral blood and only early HAART is able to pre-
serve ILCs. Late HAART therapy was not able to reconsti-
tute ILCs levels.139 Decrease in ILC subsets in HIV
infection is further confirmed by a recent report showing
the reduction of intestinal ILC subsets upon chronic
HIV-1 infection and furthermore reporting an increase in
CD94+ memory-like NK cells.140 Indeed, intestinal ILCs
in patients with HIV change their phenotypic appearance
such as expression of the IL-7Ra chain (CD127), which is
needed to sense IL-7, an important survival and prolifera-
tion factor.141 Moreover, upregulation of apoptotic signals
has been reported in ILC3s induced by plasmacytoid den-
dritic cell (pDC)-derived interferon upon HIV in human-
ized mice. Microbiota triggered IL-2 production by ILC3
has just recently been shown to support Tregs.142 It is
tempting to speculate that loss of IL-2 producing ILC
populations may have a direct effect on T-cell homeosta-
sis in HIV infection.
Furthermore, decreased ILC2 function and thus
reduced IL-13 production upon ex vivo stimulation of
SIV-infected non-human primate samples has been
reported.143 It is not yet known whether impaired ILC2
activity in HIV/SIV parallels the restraint of ILC2s in IAV
by interferon, and thereby triggers the loss of intestinal
barrier and the increased transition of microbial ligands
from the gut. IFN regulatory mechanisms upon HIV
infection may be triggered by HIV itself as well as by the
expansion of the enteric virome, but this hypothesis still
needs to be confirmed. Interestingly, virome expansion
has been reported upon SIV infections.144
dsRNA viruses: Rotavirus
Rotavirus (family of Reoviridae, dsRNA) can cause gas-
troenteritis, with young children being predominantly
affected. All three groups of IFNs are important in the
defense against Rotavirus, but type III IFNs (IFN-k) are
only acting on and triggering intestinal epithelial cell
immunity.145 Moreover, synergy between IL-22 produced
by ILC3s and IFN-c has been identified,146 further high-
lighting the strong interaction of ILCs and epithelial cells
during infection. Data are limited on the link between rota-
virus infection and microbiota; however, the efficacy of a
rotavirus vaccine (Rotarix: live, attenuated human rota-
ª 2019 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 159, 39–51 47
REVIEW SERIES: INTERACTIONS OF THE MICROBIOTA WITH THE MUCOSAL IMMUNE SYSTEM
Interaction of microbiota and ILCs
virus vaccine used in infants) and microbiota has been
noted.147 To which extend this is linked to ILC3 activity
has not yet been addressed, but would be of great interest.
Microbiota  ILCs, cancer and aging
In this last paragraph of our review we want to highlight
key aspects that are known about microbiota develop-
ment and ILC function with age, and highlight their con-
tributions to the development and defense against cancers
– one of the most common age-related diseases. As out-
lined previously, microbiota composition and function
dramatically changes in aging individuals.148 This by itself
may already alter ILC function, although one could also
imagine that altered ILC activity with age149,150 can
impact the composition of the commensal microbiota
through various mechanisms that we have reviewed
above. Several studies have reported that both dysbiosis
and altered ILC functionality can be involved in tumori-
genesis and also in the anti-tumour immune response.
These aspects have recently been discussed in excellent
reviews by Wagner and Koyasu,151 Panda and Colonna,152
Mattiola and Diefenbach,153 and Atreya et al.154 Thus, we
will only briefly touch on the role of ILCs in colon can-
cer, focusing on ILC3s, the ILC population with the
strongest link to cancer so far.
Innate lymphoid cells can be both pro- and anti-tu-
morigenic. Upon induction of intestinal inflammation by
Helicobacter hepaticus and of cancer formation with the
carcinogen azoxymethane (AOM), ILC-derived IL-22 acts
on epithelial cells and induces cancer formation. Blocking
of IL-22 or ILCs by anti-Thy1 antibody reduces colorectal
cancer.155 IL-22 can also be regulated by an endogenous
mechanism, namely by the decoy IL-22BP. Increased
expression of IL-22BP by T-cells in inflammatory bowel
disease (IBD) patients promotes cancer develop-
ment.156,157 Intestinal inflammation in IBD patients regu-
larly triggers the development of cancer,158,159 further
confirming that inflammation is an additional hallmark
of cancer.160 However, the protective role of IL-22 in
intestinal homeostasis can be extended to colon cancer.
Recently, AhR-induced IL-22 in ILC3s was shown to
reduce formation of epithelial stem cells in the
colon upon AOM treatment. The underlying mechanism
was elucidated by using the Confetti system enabling to
trace IL-22 receptor expressing or non-expressing crypts.
IL-22-deficient crypts lost the control of apoptosis
through the DNA damage response. This dysregulation
triggered the formation of colon cancer upon AOM treat-
ment, highlighting the importance of IL-22 in
colon cancer carcinogenesis.46 In the same study, they
could also demonstrate that dietary-derived AhR ligands
directly induce genotoxic stress in intestinal epithelial
cells, while at the same time promoting IL-22 production
in ILC3s, which in return switches on the DNA damage
response in intestinal epithelial cells. These studies further
underline that ILC3s are key players in homeostatic but
also in inflammatory conditions at the interface between
the environment and the body. For certain, aging and
cancers will be of interest in future studies looking at
microbiotaILC interactions.
Summary and outlook
The tremendous impact of the microbiota on health and
thus the immune system of the host has been appreciated
for a long time. The recently discovered field of ILC biol-
ogy and its importance in the establishment and regula-
tion of the host immune system provides novel insights
into the regulation and function of the hostmicrobial
mutualism. In this review, we aimed to give an overview
of recent findings on the regulatory interplay between
microbiota and ILC function throughout life at steady-
state and during disease. The microbiota is continuously
adapting to its environment throughout the lifetime. The
synergism of commensals and immune cells has a
tremendous impact on the host’s health and immune
defense. Just recently, Godinho-Silva et al. deciphered that
the circadian clock activator Antl is essential for intestinal
ILC3 function at steady-state and upon infection by
C. rodentium,161 revealing that ILC3s are controlled by
additional environmental factors. We are just beginning
to understand the complexity of these networks, and are
excited to decipher this close interaction of microbiota
and ILCs during the complete lifespan in the future.
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